Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a $25.00 price target on the stock.

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock opened at $0.88 on Friday. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. The firm has a fifty day simple moving average of $2.00 and a two-hundred day simple moving average of $1.84. Milestone Pharmaceuticals has a 12 month low of $0.75 and a 12 month high of $2.75. The firm has a market capitalization of $46.95 million, a PE ratio of -1.09 and a beta of 1.83.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp raised its stake in shares of Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares during the last quarter. Virtu Financial LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth $170,000. PVG Asset Management Corp purchased a new stake in Milestone Pharmaceuticals in the 3rd quarter valued at $46,000. Northern Trust Corp lifted its stake in Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after acquiring an additional 30,772 shares in the last quarter. Finally, Toronto Dominion Bank bought a new position in Milestone Pharmaceuticals during the 4th quarter valued at $1,770,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.